CHESTER, UK – Jan 20, 2016 – Ethicor Pharma is pleased to announce the appointment of Professor Dominic Wells to its Scientific Advisory Board.
Professor Dominic (Nic) Wells qualified from Cambridge University as a veterinary surgeon in 1984 together with a first class BA in Applied Biology. After several years in general practice in Nottinghamshire he attended the University of Wyoming in the USA. There he studied comparative exercise physiology and obtained his PhD.
Returning to the UK in 1990, he took a temporary lectureship at the Royal Veterinary College in London. In 1992 he was appointed to a full lectureship. In 1995 he moved to the Charing Cross and Westminster Medical School, now part of the Faculty of Medicine at Imperial College London. He was appointed Professor at Imperial College in October 2005. In January 2010 he moved back to the Royal Veterinary College as Professor in Translational Medicine.
Nic has been involved with neuromuscular diseases since 1990 and has extensive experience working with transgenic mice and other laboratory animals. He has been involved with a number of workshops examining welfare and best practice in animal research as well as the TREAT-NMD standardisation efforts for analysis of results in the animal models of neuromuscular diseases.
His research over the last 18 years has focused on DMD (Duchenne Muscular Dystrophy) and the generation and analysis of genetically modified mice. Nic’s laboratory is examining the factors influencing the efficiency of local and systemic administration of novel medications in animal models of DMD. He has an excellent understanding of the role and limitations of pre-clinical models for a range of conditions.
Nic recently retired as chairman of the TREAT-NMD Advisory Committee for Therapeutics (TACT); established in 2009, TACT is a unique multi-disciplinary international group of well recognised academic and industry drug development experts as well as representatives of patient foundations, who meet twice a year to review and provide guidance on the translation and development path of therapeutics programs in rare neuromuscular diseases with large unmet need, such as muscular dystrophies and amyotrophic lateral sclerosis (ALS). The confidential and comprehensive review provides recommendations including go-no-go milestones.
About Ethicor Pharma Ltd
Ethicor Pharma is engaged in the development and supply of unlicensed medicines to meet the requirements of patients who fail to respond to authorised treatments. Such products are often known as ‘specials’. Whilst these medicines are unlicensed, they are subject to rigorous quality standards imposed by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), which ensures they are made in suitable and controlled manufacturing facilities. They are stable, fit for purpose and subject to effective recall and monitoring systems. Ethicor supplies therapy options for patients with unmet clinical needs, by developing and making available a range of high-quality, stable formulations of established compounds with an acceptable shelf life, including liquids for children, solid dose and topical presentations, and injections. Ethicor also supplies an ever-expanding range of novel, patent-protected products for use under specials guidelines.
Ethicor contracts out the manufacture of all finished products to suitably authorised manufacturers Worldwide, and to UK contract manufacturers with valid UK Manufacturer of Specials licences (MS). This ensures superior quality products and packaging, and full compliance with regulatory requirements.
About Duchenne Muscular Dystrophy (DMD)
DMD is the most devastating of the muscular dystrophies. It is a genetic disease that primarily affects boys and young men. The hallmarks of DMD are skeletal muscle weakness, followed by respiratory distress and heart failure. As a degenerative disease, it inevitably leads to premature death, most commonly through respiratory failure but now increasingly through heart failure.
Forward-Looking Statement Disclaimer
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.
Distributed by Press Release Jet
Company Name: Ethicor Pharma Ltd
Contact Person: Richard Drury
Phone: +44 7785 707433
Country: United Kingdom